PCSK9 and coronary artery disorder: In our positive control analyses, genetically-proxied inhibition of HMGCR, NPC1L1 and PCSK9 were all significantly associated with lower CAD risk (corresponding ORs = 0.63; 0.50–0.80, 0.54; 0.33–0.88, and 0.51; 0.43–0.60 per SD decrease in LDL-C), consistent with existing knowledge.